
September 2022
Insist! on Better Care
Biomarker testing in multiple myeloma (MM) is essential to ensure patients are receiving the best, most personalized care available. The goal of INSIST! Myeloma is to educate and empower patients and care partners to speak up and insist on better care.

Understanding Testing in Myeloma



















Myeloma Treatment Decisions

















Downloadable Resource Guide (printer-friendly)

This program is supported by Bristol Myers Squibb/Celgene, Foundation Medicine, and Takeda, and through generous donations from people like you.